Inactive Instrument

Urovant Sciences Ltd. Stock price

Equities

UROV

BMG9381B1081

Biotechnology & Medical Research

Dynamic Chart
Urovant Sciences and Pierre Fabre Médicament Enters into Exclusive License Agreement CI
Urovant Sciences Ltd. Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting CI
Urovant Sciences Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints CI
Urovant Sciences Announces the Publication of A New, Post-Hoc Analysis of Data from the Phase 3 EMPOWUR Trial of GEMTESA 75 Mg in the International Journal of Clinical Practice CI
Urovant Sciences Announces Management Changes CI
Urovant Sciences Ltd. Announces Executive Changes CI
Urovant Sciences Names Betzy Estrada as Executive VP and Chief Human Resources Officer CI
Urovant Sciences to Present Key Data for GEMTESA® 75 Mg At the 2021 Annual Meeting of the American Urological Association CI
Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from S&P TMI Index CI
Urovant Sciences Ltd. Announces Board Changes CI
Urovant Sciences Ltd.(NasdaqGS:UROV) dropped from NASDAQ Composite Index CI
Sumitovant Biopharma Ltd. completed the acquisition of the remaining 27.6% stake in Urovant Sciences Ltd.. CI
Transcript : Urovant Sciences Ltd. - Shareholder/Analyst Call
Urovant Sciences : Posts Wider Fiscal Q3 Net Loss MT
Urovant Sciences Ltd. Reports Earnings Results for the Third Quarter Ended December 31, 2020 CI
More news
Managers TitleAgeSince
Chief Executive Officer 54 19-02-28
Director of Finance/CFO 62 19-10-27
Chief Tech/Sci/R&D Officer 66 -
Members of the board TitleAgeSince
Director/Board Member 63 20-05-19
Director/Board Member 60 18-06-30
Chief Executive Officer 54 19-02-28
More insiders
Urovant Sciences Ltd. is a biopharmaceutical company. The Company is focused on developing and commercializing therapies for a range of urologic conditions. The Company's lead product, GEMTESA (vibegron), is an oral, once-daily (75 mg) small molecule beta-3 agonist for the treatment of adult patients with overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency. GEMTESA is also being evaluated for the treatment of OAB in men with benign prostatic hyperplasia. The Company's second product candidate, URO-902, is a gene therapy being developed for patients with OAB who have failed oral pharmacologic therapy.
More about the company
  1. Stock
  2. Equities
  3. Stock Urovant Sciences Ltd. - Nasdaq